Dr. Jay Fine has a strong track record of drug discovery and development leadership in respiratory diseases, oncology, immunology and fibrotic disease indications. Dr. Fine has progressed over 30 new molecular entities into clinical development, leading to the commercial launch of multiple products including Skyrizi(TM) for Plaque Psoriasis, Psoriatic Arthritis and Crohn’s Disease and Spevigo(TM) for Generalized Pustular Psoriasis. He has chaired various governance and steering committees at global pharmaceutical companies. Dr. Fine currently serves as President of Research and Development at EvolveImmune Therapeutics, a development-stage company focused on differentiated immunotherapeutic approaches for the treatment of cancer. Previously, he served as Senior Vice President and Global Therapeutic Area Head for Immunology and Respiratory Diseases Research at Boehringer Ingelheim and served as the Discovery Research Site Head at their Ridgefield, CT location. Dr. Fine also served as Head of Translational Biology at Roche Pharmaceuticals, was Director in the Inflammation department at Schering-Plough and worked in the Biologic Response Modifiers Program at the NCI. Dr. Fine holds a B.S. degree from Cornell University and a Ph.D. from the University of Rochester School of Medicine. He has authored over 75 scientific publications and patents and has been the recipient of numerous honors and awards during his career.
